Back to Archived Journals » Current Biomarker Findings » Volume 5

A multi-biomarker disease activity score for monitoring rheumatoid arthritis

Authors Hirata S, Defranoux N, Hanami K, Yamaoka K, Tanaka Y

Received 8 April 2015

Accepted for publication 8 June 2015

Published 6 October 2015 Volume 2015:5 Pages 69—78

DOI https://doi.org/10.2147/CBF.S46912

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Hung Khong


Shintaro Hirata,1 Nadine Defranoux,2 Kentaro Hanami,1 Kunihiro Yamaoka,3 Yoshiya Tanaka1

1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; 2Crescendo Bioscience, South San Francisco, CA, USA; 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Abstract: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects the synovium and results in cartilage degradation, bone erosions, and joint deformities. RA-associated pain, decreased mobility, fatigue, and comorbidities lead to functional disability, impaired quality of life, and shortened life expectancy by 5–10 years. According to the US Centers for Disease Control, RA ranked as the 42nd highest contributor to global disability, with a prevalence of 1.5 million in the USA and 1.24 million in Japan. Synthetic and biologic disease-modifying anti-rheumatic drugs have improved patient health and disease outcomes. Early diagnosis and intervention to control and decrease disease activity have led to improved patient outcomes. Furthermore, the emergence of a treat-to-target strategy and the definition of remission criteria by the American College of Rheumatology and European League Against Rheumatology have provided a new framework for physicians to achieve better patient outcomes based on regular evaluation of disease activity and assessment of the response to treatment. Improvement is needed, however, in facilitating disease activity assessment and identifying patients at higher risk of radiographic progression and those with smoldering disease who could benefit from more aggressive intervention. An objective disease activity test based on biomarkers measured in the blood that reflects the underlying biological events in addition to information on risk of radiographic progression would fulfill this need. Such a test would provide physicians with a convenient measurement tool to monitor patients in a clinical setting and support rapid treatment adjustment and tighter disease control. This article examines peer-reviewed publications cited in PubMed that describe the multi-biomarker disease activity score, its development and validation, and its applications as an objective disease assessment tool in patients with RA.

Keywords: algorithm, multi-biomarker disease activity score, disease activity, rheumatoid arthritis, Vectra DA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]